Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121338023 | 12133802 | 3 | F | 20160218 | 20160331 | 20160301 | 20160726 | EXP | US-UNITED THERAPEUTICS-UNT-2016-002754 | UNITED THERAPEUTICS | 49.51 | YR | F | Y | 102.40000 | KG | 20160726 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121338023 | 12133802 | 1 | PS | REMODULIN | TREPROSTINIL | 1 | Subcutaneous | 0.014 ?G/KG, CONTINUING | U | U | 2100500 | 21272 | .014 | UG/KG | INJECTION | ||||
| 121338023 | 12133802 | 2 | SS | LETAIRIS | AMBRISENTAN | 1 | Unknown | 5 MG, QD | SBFP | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 121338023 | 12133802 | 1 | Pulmonary arterial hypertension |
| 121338023 | 12133802 | 2 | Pulmonary hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 121338023 | 12133802 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 121338023 | 12133802 | Dyspnoea | |
| 121338023 | 12133802 | Fluid retention |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 121338023 | 12133802 | 1 | 20140404 | 0 | ||
| 121338023 | 12133802 | 2 | 20160202 | 0 |